Trade United Therapeutics Corp - UTHR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.76 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023485% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001262% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 308.09 |
| Open | 304.95 |
| 1-Year Change | 32.8% |
| Day's Range | 303.28 - 310.54 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 308.09 | 5.64 | 1.86% | 302.45 | 308.96 | 297.97 |
| Mar 28, 2025 | 306.70 | -2.25 | -0.73% | 308.95 | 308.95 | 304.50 |
| Mar 27, 2025 | 307.82 | -3.04 | -0.98% | 310.86 | 314.41 | 307.46 |
| Mar 26, 2025 | 310.73 | -2.37 | -0.76% | 313.10 | 315.01 | 307.95 |
| Mar 25, 2025 | 316.35 | -3.46 | -1.08% | 319.81 | 320.12 | 312.31 |
| Mar 24, 2025 | 319.41 | 6.45 | 2.06% | 312.96 | 320.27 | 312.95 |
| Mar 21, 2025 | 312.79 | 2.84 | 0.92% | 309.95 | 315.00 | 309.95 |
| Mar 20, 2025 | 313.47 | -1.48 | -0.47% | 314.95 | 319.20 | 312.56 |
| Mar 19, 2025 | 318.76 | 3.69 | 1.17% | 315.07 | 318.76 | 307.02 |
| Mar 18, 2025 | 314.07 | -6.41 | -2.00% | 320.48 | 323.83 | 313.75 |
| Mar 17, 2025 | 322.81 | 16.34 | 5.33% | 306.47 | 323.96 | 304.45 |
| Mar 14, 2025 | 307.08 | 2.18 | 0.71% | 304.90 | 308.96 | 303.96 |
| Mar 13, 2025 | 305.34 | -0.77 | -0.25% | 306.11 | 307.53 | 299.51 |
| Mar 12, 2025 | 306.85 | 2.90 | 0.95% | 303.95 | 307.48 | 300.53 |
| Mar 11, 2025 | 304.03 | -9.92 | -3.16% | 313.95 | 314.54 | 303.48 |
| Mar 10, 2025 | 317.53 | 5.57 | 1.79% | 311.96 | 323.08 | 311.96 |
| Mar 7, 2025 | 315.60 | 9.55 | 3.12% | 306.05 | 320.68 | 305.54 |
| Mar 6, 2025 | 307.38 | -0.57 | -0.19% | 307.95 | 311.50 | 305.95 |
| Mar 5, 2025 | 310.64 | 0.69 | 0.22% | 309.95 | 311.94 | 306.58 |
| Mar 4, 2025 | 308.20 | 0.33 | 0.11% | 307.87 | 315.11 | 305.73 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
United Therapeutics Company profile
About United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, United Therapeutics Corporation revenues increased 14% to $1.69B. Net income decreased 8% to $475.8M. Revenues reflect Tyvaso segment increase of 26% to $607.5M, Unituxin segment increase of 65% to $202.3M, United States segment increase of 11% to $1.56B, Rest-of-World segment increase of 70% to $121.3M. Net income was offset by IPR&D asset impairment charges increase from $0K to $113.4M (expense).
Equity composition
Common Stock $.01 Par, 06/11, 245M auth., 60,817,983 issd., less 2,503,657 shs. in Treas. @ $70.1M. Insiders control 1.10%. IPO: 6/17/99, 4,500,000 @ $12 by Deutsche Banc Alex. Brown. 09/09, 2-for-1 stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
1000 Spring St
SILVER SPRING
MARYLAND 20910
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com